Allergy

Augusts 5, 2024

Carlos Colás: “Our studies have high social impact, but little investment attractiveness for the pharmaceutical industry”

In this interview, the IIS Aragón researcher talks about his work leading the 'Allergy' Group (GIIS039) at the Hospital Clínico, and what his projects are like.